Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 31 | 0.91 |
| pathways Reactome | 1 pathway; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 15549
Sealed predictions
- MTERF4 in dopamine neurons, braak+0.01 (p 0.982) → -0.65 (p 0.058)receipt 15556
Swarm cases
receipt 15556: MTERF4 in dopamine neurons, braak
- power
- full sample -0.32 (p 0.198, n 18), 95% CI -0.68 to +0.17. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.40 (p 0.103, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.35 (p 0.153, n 18). could be the mix.
- skeptic
- leave-one-out range -0.43 to -0.22, sign flips 0; without severely affected donors -0.32 (p 0.198, n 18). fragile.
- cell type
- strongest in astrocytes: +0.69 (p 0.0017, n 18) vs -0.32 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MTERF4 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MTERF4 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.13 p 0.657 (needs p < 1.5e-4)
Receipts
loading the receipts